events
News and Community
Content by Category
Artificial Intelligence in Health Tech
Medical Cloud Computing
Patient Engagement
EHR/EMR
Telehealth
Our Network
IT Tech News
CXO Insiders
Rev Tech News
Fin Tech News
HR Tech News
Client Papers
Soc News
Martech-News
events
News and Community
Content by Category
Artificial Intelligence in Health Tech
Medical Cloud Computing
Patient Engagement
EHR/EMR
Telehealth
Our Network
IT Tech News
CXO Insiders
Rev Tech News
Fin Tech News
HR Tech News
Client Papers
Soc News
Martech-News
Search
Login
events
News and Community
Content by Category
Artificial Intelligence in Health Tech
Medical Cloud Computing
Patient Engagement
EHR/EMR
Telehealth
Our Network
IT Tech News
CXO Insiders
Rev Tech News
Fin Tech News
HR Tech News
Client Papers
Soc News
Martech-News
events
News and Community
Content by Category
Artificial Intelligence in Health Tech
Medical Cloud Computing
Patient Engagement
EHR/EMR
Telehealth
Our Network
IT Tech News
CXO Insiders
Rev Tech News
Fin Tech News
HR Tech News
Client Papers
Soc News
Martech-News
Login
News and Community
Alfasigma
,
Axial Spondyloarthritis
,
Axspa Treatment
,
Filgotinib
,
Healthcare Technology
,
Inflammatory Disease
,
Jak1 Inhibitor
,
Jyseleca
,
Olinguito
,
Phase 3 Trial
,
Rheumatology
September 21, 2026
Alfasigma’s Jyseleca (filgotinib) Receives Positive CHMP Recommendation for New Axial Spondyloarthritis Indication
Load More
